Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 7Flow Cytometry 4fludarabine 3Therapeutics 3Polymerase Chain Reaction 3Nivolumab 3liposomal amphotericin B 2aldesleukin 2Voriconazole 2Psychiatric Rehabilitation 2Ondansetron 2Melphalan 2Itraconazole 2Ipilimumab 2Immunologic Techniques 2Etoposide 2Dexamethasone 2Caspofungin 2Carboplatin 2Calcium Dobesilate 2Busulfan 2Aprepitant 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2tipifarnib 1sargramostim 1pembrolizumab 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × LY2940680 × Dermatologic × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡